Mayo Clinic Gene Editing Project | New Pediatric Therapy

Mayo Clinic Advances Gene Editing for Pediatric Immune Disorders

Mayo Clinic is moving into a new phase of research as a primary clinical partner in a $27.7 million project aimed at developing scalable gene-editing treatments for children. The initiative, known as AEGIS, focuses on curing inborn errors of immunity. These conditions comprise over 500 rare genetic disorders that leave young patients susceptible to life-threatening infections, severe autoimmune reactions, and chronic complications. Many of these children currently face limited therapeutic options.

The project operates under the guidance of the Innovative Genomics Institute at the University of California, Berkeley. By joining this consortium, Mayo Clinic will serve as one of three clinical sites designated to conduct future trials. Its role involves the recruitment and long-term care of patients who may benefit from experimental gene therapies. Avni Joshi, chair of the Division of Pediatric Allergy and Immunology at Mayo Clinic, emphasizes that the strategy is to shift away from managing symptoms and toward correcting the root cause of these genetic errors. The goal is to provide one-time interventions that restore normal immune function.

The Technology Behind the AEGIS Consortium

Researchers within the AEGIS project are employing CRISPR-based technology to edit blood-forming stem cells. The procedure targets the specific genetic mutations responsible for these disorders at the cellular level. By using these advanced tools to repair errors in the stem cells, the team aims to build a treatment platform that is both affordable and accessible. This approach represents a shift in how medicine handles ultra-rare conditions that previously lacked viable cure paths.

This work is supported by funding from the Advanced Research Projects Agency for Health, also known as ARPA-H. The agency’s THRIVE program explicitly seeks to expand access to transformative genetic medicines. Mayo Clinic brings its existing infrastructure to the table, including its status as a FACT-accredited transplant center and its history with the Primary Immune Deficiency Treatment Consortium. These resources are critical for the safe integration of gene-editing technologies into clinical practice.

Future Implications for Rare Disease Treatment

Beyond the initial group of immune disorders, the AEGIS team intends to establish a broad, scalable framework for gene editing. This platform could eventually facilitate the development of treatments for hundreds of other rare genetic diseases. Success would provide a blueprint for how medical institutions can move experimental genomic medicine into the mainstream for pediatric care.

The broader industry context highlights a growing focus on genomic solutions for rare pediatric conditions. Other ongoing research efforts are also exploring the hidden codes behind gene activation and new methods for targeting genetic drivers of disease. The participation of a major medical institution like Mayo Clinic signals a maturation in how these therapies are being tested and delivered. As the project advances, the primary metric for success will be the restoration of long-term health for patients with few remaining options.